Phase 2CompletedAge-related condition
An Extension Protocol to Evaluate Dose Comparisons of Leucine-Metformin Combinations in Type 2 Diabetic Patients
An Extension of Protocol NS-0100-01 to Evaluate the Safety and Effect of Various Fixed-Dose Leucine and Metformin Combinations (NS-0100) Versus Standard Metformin Mono-therapy on Glycemic Control in Subjects With Type 2 Diabetes
- Sponsor
- NuSirt Biopharma (Industry)
- Enrollment
- 50 enrolled
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Low Metformin; Mid Metformin; High Metformin; Metformin
- Ages
- adults, older adults
- Registry
- NCT02435277
Full record on ClinicalTrials.gov
From the registry
Study NS-0100-01E is an extension of Study NS-01-0100 designed to assess safety and longer term effect (i.e., additional 8 weeks) of various fixed-dose leucine and metformin combinations (NS-0100) versus standard metformin monotherapy on glycemic control in subjects with type 2 diabetes using HbA1c as the primary endpoint.
Primary outcomes
- Change in HbA1c Levels in Patient Receiving the Various Doses of Leucine and Metformin Combinations
History
Last registry update
Results first posted
Study completion
Primary completion
Registered
Started